JP2021042193A - 免疫療法用シリカナノスフェア - Google Patents

免疫療法用シリカナノスフェア Download PDF

Info

Publication number
JP2021042193A
JP2021042193A JP2020122939A JP2020122939A JP2021042193A JP 2021042193 A JP2021042193 A JP 2021042193A JP 2020122939 A JP2020122939 A JP 2020122939A JP 2020122939 A JP2020122939 A JP 2020122939A JP 2021042193 A JP2021042193 A JP 2021042193A
Authority
JP
Japan
Prior art keywords
hsn
silica
tumor
antigen
hollow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020122939A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021042193A5 (enExample
Inventor
チャン ユアン モウ
Chung-Yuan Mou
チャン ユアン モウ
チョン スン ウー
Cheng-Hsun Wu
チョン スン ウー
シー ハン ウー
Si-Han Wu
シー ハン ウー
イ ピン チェン
Yi-Ping Chen
イ ピン チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nano Targeting & Therapy Biopharma Inc
Original Assignee
Nano Targeting & Therapy Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nano Targeting & Therapy Biopharma Inc filed Critical Nano Targeting & Therapy Biopharma Inc
Publication of JP2021042193A publication Critical patent/JP2021042193A/ja
Publication of JP2021042193A5 publication Critical patent/JP2021042193A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0001—Archaeal antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020122939A 2019-07-18 2020-07-17 免疫療法用シリカナノスフェア Pending JP2021042193A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962875842P 2019-07-18 2019-07-18
US62/875,842 2019-07-18

Publications (2)

Publication Number Publication Date
JP2021042193A true JP2021042193A (ja) 2021-03-18
JP2021042193A5 JP2021042193A5 (enExample) 2023-07-24

Family

ID=71670078

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020122939A Pending JP2021042193A (ja) 2019-07-18 2020-07-17 免疫療法用シリカナノスフェア

Country Status (6)

Country Link
US (1) US12274755B2 (enExample)
EP (1) EP3766515A1 (enExample)
JP (1) JP2021042193A (enExample)
CN (1) CN112237627A (enExample)
CA (1) CA3087227A1 (enExample)
TW (1) TWI829949B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114377120B (zh) * 2022-01-10 2023-09-22 大连理工大学 一种以病毒样颗粒为模板的二氧化硅疫苗递送系统的构建及其应用
CN114601817B (zh) * 2022-02-11 2023-01-10 国家纳米科学中心 一种可降解中空有机硅纳米粒子及其制备方法和应用
CN116999581B (zh) * 2023-08-08 2025-06-13 中南大学湘雅医院 一种靶向治疗乳腺癌的核素纳米药物及其制备方法与应用
CN120590491A (zh) * 2025-05-28 2025-09-05 中科中山药物创新研究院 基于二氧化硅载体的hiv病毒mper多肽纳米疫苗及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023697A2 (en) * 2007-08-14 2009-02-19 The Regents Of The University Of California Hollow silica nanospheres and methods of making same
JP2017048180A (ja) * 2015-08-31 2017-03-09 国立研究開発法人産業技術総合研究所 メソポーラスシリカ粒子
JP2018115145A (ja) * 2016-08-19 2018-07-26 ナショナル タイワン ユニバーシティ 生物活性成分を内包した中空シリカナノ粒子、調製プロセス、および、その応用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160038608A1 (en) 2014-08-07 2016-02-11 National Taiwan University Silica-based mesoporous carrier and delivery method of using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023697A2 (en) * 2007-08-14 2009-02-19 The Regents Of The University Of California Hollow silica nanospheres and methods of making same
JP2017048180A (ja) * 2015-08-31 2017-03-09 国立研究開発法人産業技術総合研究所 メソポーラスシリカ粒子
JP2018115145A (ja) * 2016-08-19 2018-07-26 ナショナル タイワン ユニバーシティ 生物活性成分を内包した中空シリカナノ粒子、調製プロセス、および、その応用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DELLACHERIE, MAXENCE O. ET AL.: "Covalent Conjugation of Peptide Antigen to Mesoporous Silica Rods to Enhance Cellular Responses", BIOCONJUGATE CHEM., vol. Volume 29, Issue 3, Pages 733-741, JPN6024029840, 2018, ISSN: 0005379415 *
PENG, J. ET AL.: "Hollow silica nanoparticles loaded with hydrophobic phthalocyanine for near-infrared photodynamic an", BIOMATERIALS, vol. 34(32):7905-12, JPN6024029839, 2013, ISSN: 0005586258 *

Also Published As

Publication number Publication date
TWI829949B (zh) 2024-01-21
CA3087227A1 (en) 2021-01-18
EP3766515A1 (en) 2021-01-20
US20210015943A1 (en) 2021-01-21
TW202116292A (zh) 2021-05-01
CN112237627A (zh) 2021-01-19
US12274755B2 (en) 2025-04-15

Similar Documents

Publication Publication Date Title
JP2021042193A (ja) 免疫療法用シリカナノスフェア
Zhu et al. Co-delivery of antigen and dual agonists by programmed mannose-targeted cationic lipid-hybrid polymersomes for enhanced vaccination
JP6716600B2 (ja) Ｒｎａ及び水溶性の治療有効化合物を標的細胞に送達するための脂質粒子製剤
Boks et al. MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses
Chen et al. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid
Shariat et al. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer
JP6851983B2 (ja) デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法
US20100143456A1 (en) Model membrane systems
EP2755680B1 (en) Particulate vaccine formulations
CN105792843B (zh) 佐剂组合物及包含其的疫苗组合物、以及它们的制造方法
JP2023517275A (ja) 脂質ナノ粒子
EA023397B1 (ru) Комбинированные вакцины с синтетическими наноносителями
Rueda et al. Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines
Chen et al. Smart combination of aluminum hydroxide and MF59 to induce strong cellular immune responses
US11759508B2 (en) Antigenic peptides for treatment of B-cell malignancy
JP7409594B2 (ja) 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用
Liu et al. A cell-penetrating peptide-assisted nanovaccine promotes antigen cross-presentation and anti-tumor immune response
Tahara et al. A solid-in-oil-in-water emulsion: An adjuvant-based immune-carrier enhances vaccine effect
Norling et al. Gel phase 1, 2-distearoyl-sn-glycero-3-phosphocholine-based liposomes are superior to fluid phase liposomes at augmenting both antigen presentation on major histocompatibility complex class II and costimulatory molecule display by dendritic cells in vitro
CN114939159A (zh) 一种载病毒抗原和佐剂的多级靶向载体的构建及应用
US11446390B2 (en) Antigen capturing nanoparticles for use in cancer immunotherapy
Lin et al. Nanodiamonds-in-oil emulsions elicit potent immune responses for effective vaccination and therapeutics
EP4450084A1 (en) The large extracellular loop (lel) of cd9 as an immunogenic adjuvant in lipid nanovesicles
Wu et al. Engineering W/O/W pickering emulsion for the enhanced antigen delivery and immune responses
JPWO2008105174A1 (ja) 細胞性免疫誘導用リポソーム

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250507